Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7021 to 7035 of 7679 results

  1. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

  2. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

  3. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC

  4. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    In development [GID-TA10583] Expected publication date: TBC

  5. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

  6. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued [GID-TA10382]

  7. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued [GID-TAG332]

  8. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

  9. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued [GID-TAG397]

  10. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued [GID-TA10159]

  11. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

  12. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]